Novo scraps two more heart drug trials, further dimming growth beyond obesity
By Patrick Wingrove Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed to reduce the risk of major adverse cardiovascular events, including death, non-fatal heart attack and non-fatal stroke, compared with placebo in a late-stage trial. On […]